Información de Gilead Sciences Inc, dividendo de Gilead Sciences Inc, actividades de los accionistas y más

Información de Gilead Sciences Inc Compañía

Información de la empresa

Código de la empresaGILD

Nombre de la empresaGilead Sciences Inc

Fecha de salida a bolsaJan 22, 1992

Fundada en1987

Director ejecutivoMr. Daniel P O'Day

Número de empleados17600

Tipo de títulosOrdinary Share

Fin del año fiscalJan 22

Dirección333 Lakeside Dr

CiudadFOSTER CITY

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal94404-1147

Teléfono16505743000

Sitio Webhttps://www.gilead.com/

Código de la empresaGILD

Fecha de salida a bolsaJan 22, 1992

Fundada en1987

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Ms. Johanna Mercier

Chief Commercial Officer

91.17K

+96.77%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

32.43K

+61.66%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

24.54K

+10.39%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

10.23K

+29.16%

Ms. Kelly A. Kramer

Independent Director

1.33K

--

Mr. Harish Manwani

Independent Director

--

Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.

Independent Director

--

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

--

Dr. Ted W. Love, M.D.

Director

--

Mr. Andrew D. (Andy) Dickinson

Chief Financial Officer

--

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Ms. Johanna Mercier

Chief Commercial Officer

91.17K

+96.77%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

32.43K

+61.66%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

24.54K

+10.39%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

10.23K

+29.16%

Ms. Kelly A. Kramer

Independent Director

1.33K

--

Mr. Harish Manwani

Independent Director

--

Desglose de ingresos

Divisa: USDHora de actualización: mié., 5 de mar

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Por negocioUSD

Nombre

Ganancia

Proporción

Biktarvy

13.42B

46.68%

Descovy

2.11B

7.34%

Genvoya

1.76B

6.12%

Sofosbuvir/Velpatasvir

1.59B

5.54%

Yescarta

1.57B

5.46%

Other

8.29B

28.83%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

19.50B

67.83%

Europe

4.34B

15.12%

Other Locations

2.90B

10.10%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Biktarvy

13.42B

46.68%

Descovy

2.11B

7.34%

Genvoya

1.76B

6.12%

Sofosbuvir/Velpatasvir

1.59B

5.54%

Yescarta

1.57B

5.46%

Other

8.29B

28.83%

Accionista

Hora de actualización: vie., 21 de feb

Estadísticas de accionistas

Tipo

Estadísticas de accionistas

Accionista

Proporción

The Vanguard Group, Inc.

9.23%

BlackRock Institutional Trust Company, N.A.

5.97%

Capital World Investors

5.75%

State Street Global Advisors (US)

4.84%

Capital Research Global Investors

4.65%

Other

69.52%

Estadísticas de accionistas

Accionista

Proporción

The Vanguard Group, Inc.

9.23%

BlackRock Institutional Trust Company, N.A.

5.97%

Capital World Investors

5.75%

State Street Global Advisors (US)

4.84%

Capital Research Global Investors

4.65%

Other

69.52%

Tipo

Accionista

Proporción

Investment Advisor

42.83%

Investment Advisor/Hedge Fund

35.39%

Research Firm

3.20%

Pension Fund

3.00%

Sovereign Wealth Fund

1.73%

Bank and Trust

1.70%

Hedge Fund

1.59%

Holding Company

0.18%

Insurance Company

0.15%

Other

10.19%

Participación institucional

Hora de actualización: dom., 19 de ene

Periodo de informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q1

3200

1.12B

90.03%

+2.74M

2024Q4

3313

1.12B

90.13%

+4.62M

2024Q3

3207

1.10B

88.48%

-11.55M

2024Q2

3188

1.09B

88.24%

-14.36M

2024Q1

3196

1.09B

88.13%

-22.03M

2023Q4

3252

1.10B

88.75%

-8.78M

2023Q3

3190

1.09B

88.14%

-23.57M

2023Q2

3196

1.09B

88.02%

-11.21M

2023Q1

3195

1.08B

87.26%

-11.16M

2022Q4

3203

1.08B

86.64%

+1.09M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

114.96M

9.23%

+203.24K

+0.17%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

74.46M

5.97%

-1.75M

-2.30%

Dec 31, 2024

Capital World Investors

71.70M

5.75%

-4.84M

-6.32%

Dec 31, 2024

State Street Global Advisors (US)

60.38M

4.84%

+210.06K

+0.34%

Dec 31, 2024

Capital Research Global Investors

57.94M

4.65%

-3.85M

-6.23%

Dec 31, 2024

Wellington Management Company, LLP

35.65M

2.86%

+1.05M

+3.05%

Dec 31, 2024

Fidelity Management & Research Company LLC

34.64M

2.78%

+6.41M

+22.72%

Dec 31, 2024

Dodge & Cox

32.94M

2.64%

-98.02K

-0.29%

Dec 31, 2024

Geode Capital Management, L.L.C.

28.28M

2.27%

+749.04K

+2.71%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

25.27M

2.02%

+525.67K

+2.12%

Dec 31, 2024

ETF relacionados

Hora de actualización: hace 15 horas

Nombre

Proporción

VanEck Biotech ETF

11.91%

ProShares Ultra Nasdaq Biotechnology

8.91%

Invesco Nasdaq Biotechnology ETF

8.43%

iShares Biotechnology ETF

7.28%

Federated Hermes MDT Large Cap Value ETF

5.5%

Tema Oncology ETF

5.34%

Invesco Biotechnology & Genome ETF

5.22%

VanEck Morningstar Wide Moat Value ETF

4.48%

USCF Dividend Income Fund

4.34%

TBG Dividend Focus ETF

4.32%

VanEck Biotech ETF

Proporción11.91%

ProShares Ultra Nasdaq Biotechnology

Proporción8.91%

Invesco Nasdaq Biotechnology ETF

Proporción8.43%

iShares Biotechnology ETF

Proporción7.28%

Federated Hermes MDT Large Cap Value ETF

Proporción5.5%

Tema Oncology ETF

Proporción5.34%

Invesco Biotechnology & Genome ETF

Proporción5.22%

VanEck Morningstar Wide Moat Value ETF

Proporción4.48%

USCF Dividend Income Fund

Proporción4.34%

TBG Dividend Focus ETF

Proporción4.32%

Dividendos

Un total de 18.48B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Nov 12, 2024

GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024

Dec 13, 2024

Dec 30, 2024

Dec 13, 2024

Aug 13, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024

Sep 13, 2024

Sep 27, 2024

Sep 13, 2024

Apr 26, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024

Jun 14, 2024

Jun 27, 2024

Jun 14, 2024

Feb 06, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Mar 28, 2024

Mar 14, 2024

Nov 08, 2023

GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023

Dec 15, 2023

Dec 28, 2023

Dec 14, 2023

Aug 07, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Sep 28, 2023

Sep 14, 2023

Apr 28, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jun 29, 2023

Jun 14, 2023

Feb 02, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Mar 30, 2023

Mar 14, 2023

Oct 27, 2022

GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022

Dec 15, 2022

Dec 29, 2022

Dec 14, 2022

Aug 02, 2022

GILD.NB Interim Cash Dividend of gross USD 0.73 paid on Sep 29, 2022 going ex on Sep 14, 2022

Sep 15, 2022

Sep 29, 2022

Sep 14, 2022

División de acciones

Fecha

Tipo

Relación

No datos encontrados

Fecha

Tipo

Relación

No datos encontrados

Gilead Sciences Inc

115.625USD

Gilead Sciences Inc

115.625

Descripción general

Compañía